AstraZeneca acquired MedImmune a couple years ago, which had an offshoot, VielaBio dedicated to business in China. Part of the agreement was the potenial for MedImmune/VielaBio to take control of a lab in WuXi.
https://www.astrazeneca.com/media-centre/press-releases/2018/medimmune-to-create-stand-alone-company-for-early-stage-inflammation-and-autoimmunity-biologics-28022018.html